Thank you, Mr. Chair.
In terms of the costing that has been done for pharmacare, budget 2019 announced the costing that has been done to date. This was $500 million to set up a drug agency and a strategy for high-cost drugs for rare diseases. The fall economic statement announced that Health Canada will start consultations soon in terms of the development of the strategy.
That's the costing that has been undertaken to date on pharmacare.